Arcturus Therapeutics Begins Operations in Janssen Labs

Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics to Present at Upcoming Investor Conferences

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences